Liquid Biopsy Market Report by Product (Kits & Reagents, Platforms & Instruments, and Services), Application (Cancer Therapeutic Application, Reproductive Health, and Other Therapeutic), Circulating Biomarkers (Circulating Tumour Cell, Circulating Tumour DNA, and Cell-free DNA), End-User (Hospitals, Diagnostic Laboratories, Point-of-care Testing, Academic Institutes, and Others) Countries and Company Analysis 2024-2030

Global Liquid Biopsy Market Analysis

Global Liquid Biopsy Market Size is projected to reach around US$ 10.08 Billion by 2030 from was worth US$ 3.73 Billion in 2023, with a CAGR of 15.26% between 2024 and 2030 according to Renub Research.

Liquid biopsy is a revolutionary diagnostic approach transforming cancer detection and tracking. Unlike traditional tissue biopsies, it includes studying circulating tumour components, together with DNA, RNA, or proteins, in physical fluids like blood. This non-invasive technique gives valuable insights right into a patient's molecular profile, bearing in mind early cancer detection, treatment selection, and tracking of remedy reaction. Liquid biopsy is in particular critical for detecting minimal residual disease and understanding tumour heterogeneity. Its versatility extends across numerous cancer sorts, providing a promising tool for personalized medicine. With ongoing improvements, liquid biopsy holds substantial ability to enhance precision oncology and improve patient results.

Liquid Biopsy Survey

• July 2023, the US has 18 liquid biopsy tests approved as in vitro diagnostics (IVDs) and 47 launched as laboratory-developed tests (LDTs).
• March 2024, NHS England plans to roll out liquid biopsy tests to up to 10,000 patients with suspected non-small cell lung cancer by March 2025.
• Sept 2023, Roche France, Foundation Medicine, and the Institute Gustave Roussy announced a partnership to provide liquid biopsy genomic testing to cancer patients in France.
• February 2023, Newswise reported that Italy has around 8,000 lung cancer patients who may qualify for a liquid biopsy each year to determine the best treatment course. As of 2023, Italy has almost 118,000 people living with a lung cancer diagnosis, with 77,200 cases in men.
• According to REDECAN, an estimated 279,260 new cases of cancer were diagnosed in Spain in 2023.
• In 2022, there was approximately 4,820,000 new cancer cases, and 3,210,000 cancer deaths in China.
• According to the Apollo Hospitals Health of the Nation 2024 Report, the number of cancer cases in India is expected to increase significantly, reaching approximately 15.7 lakh cases by 2025, up from 13.9 lakh cases in 2020. The report also dubs India the "cancer capital of the world"

China liquid biopsy market

The increased prevalence of cancer has contributed to the growth of the China market for liquid biopsy in recent years. In September 2023, Adicon Holdings Limited, an independent clinical laboratory company in Hangzhou, China, announced that it offers liquid biopsy tests from Guardant Health. Prevalence is increasing with every passing year and the most common type of cancers include breast cancer, lung cancer, colorectal cancer, prostate cancer, and skin cancer. It is increasing demand for advanced and improved technology and methods for cancer diagnosis and treatment, driving the market for liquid biopsy. In July 2023, China’s National Medical Products Administration (NMPA) has granted approval for Helio Genomics’ sister business Laboratory for Advanced Medicine and Health Group’s (LAMH) cfDNA liver cancer detection test.

liquid biopsy market Key Players

F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Thermo Fisher Scientific Inc., Johnson & Johnson, Biocept Inc., Guardant Health, Illumina, Inc., Laboratory Corporation of America Holdings, QIAGEN N.V, and Exact Sciences Corporation represent the primary contenders in the worldwide liquid biopsy sector.
Liquid Biopsy Market News

F. Hoffmann-La Roche Ltd., 

• Approved by the US FDA in October 2020 for use as a companion diagnostic (CDx) for a broader group of therapies to treat non-small cell lung cancer (NSCLC)
• June 2022, F. Hoffmann-La Roche Ltd. partnered with the Lung Cancer Research Foundation (LCRF) and Lung Cancer Mutation Consortium (LCMC) to participate in the LCMC 4th screening trial to evaluate actionable drivers in early-stage lung cancer to offer targeted therapy options for patients.
• November 2022, Thermo Fisher Scientific introduced digital PCR liquid-biopsy assays for its Applied Biosystems absolute Q dPCR system and a custom design tool to simplify cancer research in academics & clinical research institutes.
• Bio-Rad Laboratories, 
• Bio-Rad’s ddPCR technology detects cancer subtypes, monitors residual disease, optimizes drug treatment plans, and studies tumor evolution. ddPCR assays have advantages when used in liquid biopsies, enabling measurement of Circulating Tumor Cells (CTCs) and Circulating Nucleic Acids (cfDNA) in blood samples.

Thermo Fisher Scientific Inc.,

• The first assays to measure myeloid measurable residual disease (MRD) using both DNA and RNA were released by Thermo Fisher Scientific in August 2023. This makes it easier for doctors to keep an eye on this particular kind of illness.
• November 2022, Thermo Fisher Scientific tabled digital PCR liquid-biopsy assays for Applied Biosystems absolute Q dPCR system and custom design tool for simplifying cancer research in clinical research and academic institutes.
• September 2021: Thermo Fisher Scientific Inc. collaborated with AstraZeneca to develop NGS-based (CDx) to support AstraZeneca's expanding portfolio of targeted therapies.
• September 2021, Thermo Fisher Scientific launched the Applied Biosystems QuantStudio Absolute Q digital PCR system. The system uses microfluidic array technology and simplified workflows to run liquid biopsy assays to identify genetic and cancer mutations.

Biocept Inc.,

• in July 2021, obtained a South Korean patent for Primer-Switch technology. This technology finds mutations in circulating tumor DNA via real-time PCR and associated methods, which helps identify rare cancer biomarkers.

Guardant Health,

• January 2023, Guardant Health received FDA approval for Guardant360 CDx, a liquid biopsy assay as a companion diagnostic for ESR1 mutant breast cancer diagnosis.
• December 2022, Guardant Health, Inc. entered into a partnership with Susan G. Komen for conducting clinical studies to identify patients suffering from breast cancer through Guardant Reveal, a blood-based test
• May 2021, Guardant Health, Inc., received the U.S. FDA approval for the Guardant360 CDx test as the first and only test for the diagnosis of advanced non-small cell lung cancer.
• In June 2021, Guardant Health, Inc. expanded its product portfolio by adding Guardant360 Response, a blood-based test for immunotherapy and targeted therapy.
• February 2021, Guardant Health, Inc. launched a Guardant reveal test for residual disease and recurrence monitoring in patients with early-stage colorectal cancer. The test detects the residual disease after surgery and recurrence months earlier than current standard-of-care methods.

Illumina, Inc.,

• June 2021 Illumina Inc. and Next Generation Genomic Co., Ltd. launched VeriSeq NIPT Solution v2 in Southeast Asia.
• November 2023, Illumina Inc. announced the launch of TruSight Oncology 500 ctDNA v2, a novel generation of liquid biopsy assay to enable genomic profiling
• May 2022: Guardant Health, Inc. announced that blood sample-based cancer testing services in Europe are operational at the Vall d’Hebron Institute of Oncology (VHIO) liquid biopsy testing facility in Barcelona.
• In 2021, Illumina, Inc. collaborated with Bristol Myers Squibb to innovate and enhance companion diagnostics for therapy selection to further precision oncology. TSO 500 ctDNA is one of the first liquid biopsy assays to enable comprehensive genomic profiling for therapy selection.

QIAGEN N.V

• In 2021, QIAGEN collaborated with Sysmex Corporation for the development and commercialization of cancer companion diagnostics using NGS and Plasma-Safe-SeqS technology.
• In January 2022, QIAGEN's Biotech Grants program winners were announced, displaying the company's dedication to fostering partnerships with biotech and pharma firms. Supporting these businesses, QIAGEN aims to bolster their success in the market, contributing to its revenue growth strategy
• Therascreen EGFR Plus RGQ PCR Kit, a new diagnostic test from QIAGEN, was introduced in May 2023. It is employed to identify sensitive mutations in the EGFR gene, which is significant for several diseases. 
• In April 2023, QIAGEN N.V., a provider of molecular test solutions, announced the launch of QIAseq targeted cfDNA ultra panels. It enables the research activities for cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries.
• July 2021: QIAGEN collaborated with Sysmex Corporation to develop cancer companion diagnostics using ultra-sensitive liquid biopsy next-generation sequencer technology.

Exact Sciences Corporation

• In January 2022, Exact Sciences Corporation expanded its cancer diagnostics portfolio by acquiring Prevention Genetics, a genetic testing laboratory. This strategic move enables Exact Sciences to venture into hereditary cancer testing, complementing its existing offerings and enhancing its position in the diagnostics market
• August 2021, a research group at Exact Sciences and UW-Madison started working on liquid biopsies for cancer, including a blood test that helps detect genetic mutations in tumors targeted by drugs. This test can detect recurrence of cancer after treatment as well as help in the early detection of the disease.

Product

1.    Kits & Reagents
2.    Platforms & Instruments
3.    Services

Application

1.    Cancer Therapeutic Application
2.    Reproductive Health
3.    Other Therapeutic

Circulating Biomarkers

1.    Circulating Tumour Cell
2.    Circulating Tumour DNA
3.    Cell-free DNA

End-User

1.    Hospitals
2.    Diagnostic Laboratories
3.    Point-of-care Testing
4.    Academic Institutes
5.    Others

Country

1.    Americas

1.1    United States
1.2    Canada
1.3    Mexico
1.4    Brazil

2.    Europe

2.1    United Kingdom
2.2    Germany
2.3    France
2.4    Italy
2.5    Spain
2.6    Netherlands

3.    Asia – Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Australia

4.    Middle East & Africa

4.1    United Arab Emirates
4.2    South Africa

5.    Rest of the World

All companies have been covered from 3 viewpoints:

•    Overview
•    Recent Development
•    Revenue 

Company Analysis:

1.    F. Hoffmann-La Roche Ltd.
2.    Bio-Rad Laboratories
3.    Thermo Fisher Scientific Inc.
4.    Johnson & Johnson
5.    Biocept Inc.
6.    Guardant Health
7.    Illumina, Inc.
8.    Laboratory Corporation of America Holdings
9.    QIAGEN N.V.
10.    Exact Sciences Corporation

Report Details: